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Abstract: Introduction: Conversion disorder is a condition in which the patient shows psychological stress in physical
ways. This study aimed to compare the effects of haloperidol versus midazolam in patients with conversion
disorder. Methods: This double-blind randomized clinical trial was conducted on patients with conversion dis-
order who had presented to the emergency department, throughout 2015. Patients were randomly divided into
two groups and were either treated with 2.5 mg of intravenous (IV) haloperidol or 2.5 mg of IV midazolam. Re-
covery rate, time to recovery, and side effects of both drugs 1 hour, 24 hours, and 1 week after treatment were
compared using SPSS19. Results: 140 patients were divided into two groups of 70. There were no significant
differences between the groups regarding the baseline characteristics. 12 (17.1%) patients who were treated
with IV haloperidol experienced drug side effects within 1 hour and 12 (17.1%) within 24 hours, while only 3
(4.3%) patients in IV midazolam experienced side-effects within 1 hour after drug administration (p = 0.026).
The symptoms of the disease subsided in 45 (success rate: 64.3%) patients in midazolam and in 64 (success rate:
91.5%) participants in haloperidol group (P<0.001). Mean recovery time was 31.24 ± 7.03 minutes in IV mida-
zolam and 30.53 ± 7.11 minutes in IV haloperidol group (p = 0.592). Absolute risk reduction (ARR) of treating
patients with haloperidol compared to midazolam is about 27%. Conclusion: The response of patients to treat-
ment with haloperidol is clearly better than midazolam. Although more transient and minor side-effects were
observed in the group treated with haloperidol compared to midazolam group, serious side-effects were rare for
both treatments.
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1. Introduction
A
large number of patients with physical manifesta-
tions of underlying psychological disorders present
to the emergency department annually (1). Conver-
sion disorder (CD) or hysteria is a diagnostic category de-
fined in some psychiatric classification systems under the
main branch of somatoform disorders. This disorder is more
prominent in women, early adulthood, and uneducated pa-
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tients. The symptoms may be established unconsciously
and involuntarily (2). This illness is more frequent in histri-
onic personalities. Clinical signs of the disease include a
wide range of different organs being involved: Movement
disorders including paralysis, ataxia, and aphonia, sensory
disorders including blindness, anosmia and Stocking-Glove
paresthesia, and consciousness disorders including coma
and pseudo-seizure (3-6). Based on studies in non-emergent
cases, the best management for long-term treatment is be-
havioral therapy accompanied by treating other underling
psychological impairments (4-6). However, the management
of patient’s signs and symptoms in the emergency depart-
ment is quite necessary because it helps the patients and
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their families to overcome one of the most stressful situa-
tions they have ever been faced with. So, administration of
the required drugs is essential to alleviate the symptoms as
soon as possible. Since years ago, administration of haloperi-
dol and some types of benzodiazepines like Lorazepam and
Diazepam as well as Lithium and Sodium valproate was a
common practice in management of psychiatric emergen-
cies, particularly in conversion disorders, and their efficacies
have been approved so far (7, 8).
Considering the high frequency of patients with psycholog-
ical or neurological problems, especially conversion disor-
ders, admitted to emergency departments and the urgent
need to reduce the severity of symptoms in order to tranquil-
ize tremulous patients and their relatives, and since haloperi-
dol has more side-effects than midazolam, which has a
rapid effect and is available in most cases (2, 6, 7), we de-
cided to evaluate and compare the effects of intravenous (IV)
haloperidol and midazolam in patients with conversion dis-
orders presenting to emergency departments.
2. Methods:
2.1. Study Design and setting
This double-blind parallel randomized clinical trial was con-
ducted on 140 patients with conversion disorder (based on
DSM-IV, Diagnostic and Statistical Manual of Mental Dis-
orders, 4th Edition) who had presented to emergency de-
partment of Shahid Sadoughi Hospital, Yazd, central Iran, in
2015. The protocol of this research project was approved
by the Ethics Committee of Shahid Sadoughi University of
Medical Sciences and registered on Iranian Registry of Clini-
cal Trial (Trial registration number: IRCT 2015100712050N2).
We did not perform any additional invasive procedures and
patient’s written consent was taken. The purpose of the
study was explained to the patients. A written consent form
was obtained from all patients and patients’ information re-
mained confidential. Patients were informed of the probable
drug side-effects and recommended to come back in case of
the mentioned complications happening. Ethical issues re-
lated to human studies (according to the Helsinki Statement)
were considered.
2.2. Participants
All patients aged 18 to 60 years who met the following in-
clusion criteria were enrolled in the study: any alteration or
impairment in daily performances, an experience of recent
emotional stress, a symptom or deficit that could not be ex-
plained by another medical or mental disorder, and a symp-
tom or deficit that was not restricted to pain or sexual disor-
ders.
The exclusion criteria were as follows: patients with ab-
normal vital signs, pregnant or lactating women, addicted
patients, patients with known hepatic or renal failure, se-
vere cardio-pulmonary impairment, cases of parkinsonism,
a history of recent seizure or patients who were taking anti-
epileptic agents, long Q-T syndrome, having allergies to neu-
roleptics or benzodiazepines, a history of psychiatric disor-
ders, and patients who did not sign the informed written con-
sent.
2.3. Procedures
After patients’ admission to the emergency department,
conversion disorder diagnosis was made by an emergency
medicine specialist, based on DSM-IV, Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th Edition. After evalu-
ating eligibility criteria, history taking and physical examina-
tion were done by an emergency medicine resident and the
data were recorded.
The participating patients were randomly assigned to the two
groups based on the table of random numbers by an in-
dependent physician blind to the study (random sequence
number generation was done by a computer).
2.5 mg of IV haloperidol (HALODIC, 5 mg/1mL, Exir Pharma-
ceutical Co.) was administered to the patients in group A and
2.5 mg of IV midazolam (Midazolam Aburaihan, 5 mg/1ml,
Aburaihan Pharmaceutical Co.) was prescribed for patients
in group B (based on reliable guidelines). The drugs were
administered to the patients by a trained nurse, and the as-
sessor was blind. After drug administration, all patients re-
mained under direct supervision of an emergency medicine
resident with concurrent cardiac monitoring (heart rate, O2
saturation, diastolic blood pressure, systolic blood pressure).
The patients were followed up through the next 24 h and 1
week after treatment. The outcomes were recorded. All pa-
tients and emergency staff including physicians, nurses, and
researchers were blind to the therapeutic groups.
2.4. Data Gathering
A questionnaire was completed for all the patients including
demographic data, marital status, level of education, recent
emotional stress, taking medications, underlying physical ill-
ness, movement disorders, sensory disorders, consciousness
disorders, recovery rate, time of recovery, and side-effects in
both groups. A trained emergency medicine resident was re-
sponsible for data gathering.
2.5. Outcome
Recovery rate (acute symptoms subsiding), time to recov-
ery, and side-effects of haloperidol (extrapyramidal and an-
ticholinergic side-effects, and hypotension) and midazolam
(decreased respiratory rate, apnea, drowsiness, nausea, vom-
iting) at 1 hour, 24 hours, and 1 week after treatment were
considered as main study outcomes and compared between
the groups.
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Figure 1: Follow-up of candidates for receiving intravenous haloperidol or midazolam (according to consort statement).
2.6. Statistical analysis
The participants were selected via convenience sampling
method. The sample size was determined to be at least 52
patients in each group and it was achieved by 95% confi-
dence coefficient (α=0.05) and power of 80% (β=0.2); how-
ever, 70 subjects were included in each group. The data were
analyzed by an experienced statistics consultant. All the col-
lected data were imported to SPSS19 (IBM, SPSS statics for
windows, Armonk, IBM Corp.) and analyzed using statisti-
cal tests. Mean and standard deviation (SD) for quantitative
variables and frequencies (percentages) for qualitative vari-
ables were calculated. To compare the quantitative variables
between two groups, independent Student’s t-test (or Mann-
Whitney test) was used and categorical variables were com-
pared between the two groups using the Chi-square test. P <
0.05 was considered as statistically significant.
3. Results
3.1. Baseline characteristics
140 patients with conversion disorder manifestations were
enrolled (Figure 1). Patients were randomly divided into two
groups of 70: group A who were treated with haloperidol, and
group B who received midazolam. The mean age of patients
in midazolam and haloperidol groups was 29.67± 7.50 and
29.54 ± 7.22 years, respectively (p = 0.918). Table 1 compares
the baseline characteristics of studied patients between the
groups. There were no significant differences between the
groups regarding the means of educational level (p = 0.988),
marital status (p = 1.00) and sex (p = 0.365).
3.2. Outcomes
12 (17.1%) patients who were treated with IV haloperidol
experienced drug side-effects within 1 hour and 12 (17.1%)
within 24 hours, while only 3 (4.3%) patients in IV midazolam
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Table 1: Comparing baseline characteristics of patients with conversion disorder treated with IV midazolam (n = 70) and IV haloperidol (n =
70)
Variable Midazolam Haloperidol P
Age (year)
Mean ± SD 29.67 ± 7.50 29.54 ±7.22 0.918
Sex
Male 29 (41.4) 26 (37.1) 0.365
Female 41 (58.6) 44 (62.9)
Marital status
Single 23 (32.9) 24 (43.3) 1.000
Married 47 (67.1) 46 (65.7)
Level of education
Uneducated 4 (5.7) 4 (5.7)
Junior school 30 (42.9) 28 (40.0) 0.998
High school 23 (32.9) 24 (43.3)
Bachelor and higher 13 (18.6) 14 (20.0)
Recent emotional stress
Yes - - -
No 70 (100.0) 70 (100.0)
Taking medications
Yes - - -
No 70 (100.0) 70 (100.0)
Underlying physical illness
Yes - - -
No 70 (100.0) 70 (100.0)
Movement disorders
No 44 (62.9) 43 (61.4)
Paralysis 16 (22.9) 15 (21.4) 0.893
Aphonic 10 (14.3) 12 (17.1)
Sensory disorders
No 54 (77.1) 53 (75.7) 1.000
Stocking-glove 16 (22.9) 17 (24.3)
Consciousness disorders
No 42 (60) 44 (62.9)
Coma 13 (18.6) 14 (20) 0.812
Seizure 15 (21.4) 12 (17.1)
Vital signs
Heart Rate 79.59 ± 4.14 79.60 ± 3.99 0.983
O2 Saturation 95.39 ±1.19 95.41 ± 1.25 0.891
DBP 76.43 ± 7.80 76.57 ± 7.64 0.913
SBP 117.86 ± 8.14 118.43 ± 8.45 0.684
Data were presented as mean ± standard deviation or frequency (%). DBP: Diastolic blood pressure, SBP: Systolic blood pressure.
experienced side-effects within 1 hour after drug administra-
tion (p = 0.026). The symptoms of the disease subsided in 45
(success rate: 64.3%) patients in midazolam and 64 (success
rate: 91.5%) patients in haloperidol group (P<0.001). Mean
recovery time was 31.24 ± 7.03 minutes in IV midazolam and
30.53 ± 7.11 minutes in IV haloperidol group (p = 0.592). Ab-
solute risk reduction (ARR) of treating patients with haloperi-
dol compared to midazolam is about 27%.
4. Discussion
The results of this clinical trial showed that the success rate
of IV haloperidol in managing conversion disorder is signif-
icantly higher than midazolam (91.5% versus 64.3%). How-
ever, patients who were treated with IV haloperidol expe-
rienced more transient and minor side-effects 1 hour, 24
hours, and 1 week after treatment. Serious side-effects for
both treatments were rare.
In a study conducted by Esmailian et al. (2015) the efficacy
and safety of haloperidol and midazolam have been evalu-
ated in management of 48 patients with manifestations of
conversion disorder, who were admitted to the emergency
department. The efficacy of both drugs in alleviating the
symptoms of the disease was reported to be the same (9).
In another study conducted by Nobay et al. (2003), the effects
of 3 medications including midazolam, haloperidol, and Lo-
razepam were evaluated in patients with behavioral disor-
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ders. The results showed that the efficacy of all 3 drugs was
the same (10). The effects of haloperidol plus promethazine
vs midazolam were investigated in sedation of agitated pa-
tients presenting to the psychiatric emergency room in an-
other study. Their study showed that both treatments were
effective (11). The difference between the results of this study
and previous studies almost all of which indicate that mida-
zolam is more effective on psychological stresses, may be at-
tributed to the design and the drugs used. In addition, our
study was held in the emergency department of a large teach-
ing hospital in South and South East of Iran with a high fre-
quency of new patient admission. This means that the re-
searchers of the study were often under excessive pressure
and that they may have been at the risk of over-assessment
(12). Despite the complications of haloperidol, it is currently
still the drug of choice in emergency situations (13). In the
mid-1980s, several studies looked at the effect of haloperidol
in treatment of devastating diseases (10, 14).
In this study, we observed that haloperidol is effective in
91.5% of cases. However, midazolam was only effective in
64.3% of patients. In another study, similar results have been
reported in 81 patients. In addition, further research is re-
quired to discover drugs with faster and better effect to use in
combination with other drugs (15).
The present study investigated the clinical effects of mida-
zolam and haloperidol in patients with conversion disorder
at 1 h, 24 h and one week after administration. In the two
intervals of 1 and 24 h after initiation of treatment, the side-
effects of haloperidol were significantly higher than midazo-
lam. Contrary to the results of the present study, Huf et al.
(2003) reported that side-effects of haloperidol plus promet-
hazine are not significantly more than midazolam in patients
with conversion disorder (11). In another study, Powney et al.
(2012) reported the results of 32 previous studies that mea-
sured the effects of haloperidol compared to other therapies.
According to the study, two clinical trials have reported that
patients in the haloperidol group had experienced one or
more adverse events compared to the placebo group (n=395,
RR=1.64, CI 1.2323-2.20) (16).
According to the results of the present trial as well as previ-
ous studies, it is clear that the probable side-effects of both
drugs are mostly seen within the first few minutes after ad-
ministration. In the study by Huf et al. (2003), it is re-
ported that both cases of severe side-effects occurred in the
first 20 min after injection of haloperidol and midazolam and
they have been associated with other factors. So, preparing
for probable side-effects in the first few minutes after injec-
tion as well as considering the patient’s clinical records such
as a history of epilepsy or drug consumption are necessary
(11). It suggested that future studies investigate the sedation
speed, type and severity of side-effects, and optimal dose of
haloperidol and midazolam, and the effect of combination
therapy with haloperidol and midazolam in patients with
conversion disorder. In addition, to assess the possible in-
fluence of stressful situations in emergency department, do-
ing further studies in other wards of the hospital with calmer
conditions is recommended.
5. Limitation
Sedation speed and severity of side-effects were not investi-
gated in this single-center study. The main limitation of the
present study was that we did not consider a group treated by
combination therapy with haloperidol and midazolam.
6. Conclusion
Based on the results, the response of patients to treatment
with haloperidol is clearly better than midazolam. Although
transient and minor side-effects in the group treated with
haloperidol were more than midazolam, serious side-effects
were rare for both treatments.
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